Advertisement
Conference Call Details:
The conference call will be webcast simultaneously over the Internet.Please visit the Investor Relations section of the Advanced Life Sciencescorporate website www.advancedlifesciences.com. Alternatively, callers mayparticipate in the conference call by dialing 888-680-0894(domestic) or617-213-4860(international). The passcode for the conference call is31431743. A replay of the conference call will be available until April 17,2008. Callers may access the telephone replay by dialing 888-286-8010(domestic) or 617-801-6888 (international), passcode 33735345. Investors areadvised to dial into the call at least ten minutes prior to the call toregister. Participants may pre-register for the call athttps://www.theconferencingservice.com/prereg/key.process?key=PXKLGN4DD.Pre-registrants will be issued a pin number to use when dialing into the livecall which will provide quick access to the conference by bypassing theoperator upon connection.
Advertisement
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in thediscovery, development and commercialization of novel drugs in the therapeuticareas of infection, cancer and respiratory diseases. The Company's leadcandidate, cethromycin, is a novel once-a-day oral antibiotic in late-stagedevelopment for the treatment of respiratory tract infections including CAP.For more information, please visit us on the web atwww.advancedlifesciences.com.
Forward-Looking Statements
Any statements contained in this press release that relate to futureplans, events or performance are forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Forward-lookingstatements represent our management's judgment regarding future events. TheCompany does not undertake any obligations to update any forward-lookingstatements whether as a result of new information, future events or otherwise.Our actual results could differ materially from those discussed herein due toseveral factors including the success and timing of a commercial partnershipand our ability to obtain and maintain regulatory approval and labeling of ourproduct candidates; our plans to develop and commercialize our productcandidates; the loss of key scientific or management personnel; the size andgrowth of potential markets for our product candidates and our ability toserve those markets; regulatory developments in the U.S. and foreigncountries; the rate and degree of market acceptance of any future products;the accuracy of our estimates regarding expenses, future revenues and capitalrequirements; our ability to obtain financing on terms acceptable to us; ourability to obtain and maintain intellectual property protection for ourproduct candidates; the successful development of our sales and marketingcapabilities; the success of competing drugs that become available; and theperformance of third party collaborators and manufacturers. These andadditional risks and uncertainties are detailed in the Company's filings withthe Securities and Exchange Commission.
SOURCE Advanced Life Sciences Holdings, Inc.
